Prolonged Lenalidomide Induction Does Not Significantly Impair Stem Cell Collection in Multiple Myeloma Patients Mobilized With Cyclophosphamide or Plerixafor: A Report From The Covid Era.
Name:
Publisher version
View Source
Access full-text PDFOpen Access
View Source
Check access options
Check access options
Date
2022-03-28Journal
Clinical lymphoma, Myeloma & LeukemiaPublisher
ElsevierType
Article
Metadata
Show full item recordSee at
https://doi.org/10.1016/j.clml.2022.03.013http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8958842/
Abstract
Patients who received prolonged induction were more likely to require >1 day of apheresis (38% vs. 15%; OR 3.45; P = .0154), and there was a significant correlation between the duration of lenalidomide treatment and the apheresis time required to collect sufficient cells for transplant (R2 = 0.06423, P = .0148). However, there was no significant difference between patients who received prolonged induction and those who did not with respect to CD34+ stem cell yields at completion of apheresis (9.99 vs. 10.46 cells/Kg, P = .5513) or on the first day of collection (8.29 vs. 9.59 cells/Kg, P = .1788).Rights/Terms
Copyright © 2022. Published by Elsevier Inc.Keyword
Apheresis multiple myelomaApheresis time multiple myeloma
Autologous stem cell transplant
Lenalidomide multiple myeloma
Stem cell harvest
Identifier to cite or link to this item
http://hdl.handle.net/10713/18802ae974a485f413a2113503eed53cd6c53
10.1016/j.clml.2022.03.013
Scopus Count
Collections
Related articles
- Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: A single center comparison of GCSF+/-plerixafor vs cyclophosphamide/GCSF+/-plerixafor.
- Authors: Yang C, Dehghani M, Hopman W, Bhella S
- Issue date: 2022 Aug
- A comparison of chemo-free strategy with G-CSF plus plerixafor on demand versus intermediate-dose cyclophosphamide and G-CSF as PBSC mobilization in newly diagnosed multiple myeloma patients: An Italian explorative cost Analysis.
- Authors: Laszlo D, Marcacci GP, Martino M, Radice D, Rabascio C, Lucchetti B, Magarò A, Caime A, Menna S, Lionetti MT, Bertolini F
- Issue date: 2020 Oct
- Stem Cell Mobilization in Multiple Myeloma: Comparing Safety and Efficacy of Cyclophosphamide +/- Plerixafor versus Granulocyte Colony-Stimulating Factor +/- Plerixafor in the Lenalidomide Era.
- Authors: Johnsrud A, Ladha A, Muffly L, Shiraz P, Goldstein G, Osgood V, Shizuru JA, Johnston L, Arai S, Weng WK, Lowsky R, Rezvani AR, Meyer EH, Frank MJ, Negrin RS, Miklos DB, Sidana S
- Issue date: 2021 Jul
- Multiple Myeloma: Risk Adapted Use of Plerixafor for Stem Cell Mobilization Prior to Autologous Stem Cell Transplantation is Effective and Cost Efficient.
- Authors: Prakash VS, Malik PS, Sahoo RK, Pramanik R, Choudhary P, Varshney AN, Kumar L
- Issue date: 2022 Jan
- Impact of Plerixafor Use at Different Peripheral Blood CD34(+) Thresholds on Autologous Stem Cell Collection in Patients with Multiple Myeloma.
- Authors: Shah EE, Young RP, Wong SW, Damon LE, Wolf JL, Shah ND, Leavitt AD, Loeffler P, Martin TG 3rd
- Issue date: 2020 May